Keytruda, Inlyta combo improves OS by 47%, PFS by 31% in first-line RCC

Merck & Co. reported detailed data from the Phase III KEYNOTE-426 trial of Keytruda pembrolizumab plus Inlyta axitinib as first-line treatment of renal cell carcinoma. New data showed that the combination significantly improved overall survival by 47% (median OS not reached in either group, HR=0.53, 95% CI: 0.38, 0.74, p<0.0001) and progression-free survival by 31% (median PFS of 15.1 vs. 11.1 months, HR=0.69, 95% CI: 0.57, 0.84, p=0.0001) vs. Sutent sunitinib.

Merck & Co. Inc. (NYSE:MRK) previously reported that Keytruda plus Inlyta met the primary OS and PFS endpoints but did not disclose details (see "Keytruda, Inlyta Combo Headed for First-line RCC Submissions")...